Powder: -20°C for 3 years | In solvent: -80°C for 1 year
NSC781406 is a highly effective inhibitor of PI3K and mTOR (IC50: 2 nM for PI3Kα).
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 11,000 | |||
5 mg | 在庫あり | ¥ 22,500 | |||
10 mg | 在庫あり | ¥ 37,500 | |||
25 mg | 在庫あり | ¥ 68,500 | |||
50 mg | 在庫あり | ¥ 112,500 | |||
100 mg | 在庫あり | ¥ 164,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 31,000 |
説明 | NSC781406 is a highly effective inhibitor of PI3K and mTOR (IC50: 2 nM for PI3Kα). |
ターゲット&IC50 | mTOR:5.4 nM, PI3Kγ:2.7 nM, PI3Kα:2 nM, PI3Kβ:9.4 nM, PI3Kδ:14 nM |
In vitro | NSC781406 shows reasonable liver microsome stability. NSC781406 displays effective PI3K inhibition (PI3Kα IC50=2.0 nM) that translates into BEL-7404 cells proliferation inhibition (IC50=20 nM) and it also demonstrates cytotoxic activities against leukemia, non-small cell, lung cancer, colon cancer, central nervous system cancer, melanoma, ovarian cancer, renal cancer, prostate cancer, and breast cancer. It is effective against 60 cancer cell lines with a mean GI50 value of 65 nM and with a GI50 value of less than 10 nM against four cancer cell lines. |
In vivo | NSC781406 is well tolerated at 30 mg/kg, with no observed mortality or significant reduction of body weight. NSC781406(30 mg/kg) treatment, causes statistically significant antitumor activity, in the xenograft models. It has a mean reduction in the relative tumor volume ratio of 52%. Sorafenib shows an inhibition ratio of 44% at 50 mg/kg . |
分子量 | 627.68 |
分子式 | C29H27F2N5O5S2 |
CAS No. | 1676893-24-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 150 mg/mL (238.98 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
NSC781406 1676893-24-5 PI3K/Akt/mTOR signaling PI3K mTOR Phosphoinositide 3-kinase Mammalian target of Rapamycin Inhibitor inhibit NSC 781406 NSC-781406 inhibitor